Anthony Davenport

Professor Anthony Davenport serves as Professor of Cardiovascular Pharmacology at the University of Cambridge, where he directs the Human Receptor Research group within the Department of Medicine. He holds appointments in the Experimental Medicine and Immunotherapeutics (EMIT) division and is a key member of the Cambridge Cardiovascular Interdisciplinary Research Centre (IRC), contributing to one of the world's leading cardiovascular research ecosystems.

Professor Davenport's research program centers on G-protein coupled receptors, with specialized expertise in the apelin and endothelin systems. His work spans molecular pharmacology, structural biology, and clinical investigations, examining how these receptor systems regulate cardiovascular function and contribute to disease pathogenesis. His research has important implications for understanding microvascular angina, cardiac allograft vasculopathy, cardiorenal interactions, and vascular complications in pregnancy and transplantation.

Analysis of Professor Davenport's recent publication record reveals a cohesive research trajectory focused on receptor pharmacology with direct clinical applications. His work demonstrates how the apelin system interacts with renal function in chronic kidney disease, how endothelin signaling contributes to microvascular dysfunction, and how targeting these pathways might yield novel therapeutic approaches. His research bridges basic molecular mechanisms with clinical applications, as evidenced by his clinical trials investigating zibotentan for microvascular angina and examining apelin's effects in patient populations.

As Director of the Human Receptor Research group, Professor Davenport leads a team investigating receptor-ligand interactions, particularly examining peptide versus small molecule binding at the apelin receptor. His group also explores the co-localization of receptor systems in human tissues, such as the relationship between SGLT-2 channels and endothelin receptors in cardiorenal tissue, suggesting potential synergistic therapeutic approaches for cardiovascular and metabolic conditions.